Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | IARS1 | P41252 | 6/20 | 0.35 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30059707 | 0.88 | NAAA (0.42) | TP53NOD1 | |
| SCHEMBL30060281 | 0.88 | NAAA (0.42) | TP53NOD1 | |
| SCHEMBL30059307 | 0.88 | NAAA (0.42) | TP53NOD1 | |
| SCHEMBL30058717 | 0.88 | TP53 (0.38) | TP53NOD1DPP4DPP8DPP9 | |
| SCHEMBL29377485 | 0.81 | FAAH (0.44) | TP53 | |
| SCHEMBL30177052 | 0.81 | SLC7A5 (0.37) | TP53NOD1 | |
| SCHEMBL29652215 | 0.80 | NOD1 (0.48) | TP53NOD1 | |
| SCHEMBL29652217 | 0.80 | NOD1 (0.48) | TP53NOD1 | |
| SCHEMBL16007385 | 0.80 | NAAA (0.48) | NOD1 | |
| SCHEMBL1479612 | 0.80 | NAAA (0.48) | NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12251457-B2 | Self-neutralizing amino acid based cationic compositions | INOLEX INVESTMENT CORPORATION (US) | 2025-03-18 | — | — | US | claimed |
| US-20230092150-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORPORATION | 2023-03-23 | — | — | US | claimed |
| US-11540991-B2 | Self-neutralizing amino acid based cationic compositions | INOLEX INVESTMENT CORPORATION (US) | 2023-01-03 | — | — | US | claimed |
| US-20250186322-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORP (US) | 2025-06-12 | — | — | US | disclosed |
| US-12251457-B2 | Self-neutralizing amino acid based cationic compositions | INOLEX INVESTMENT CORPORATION (US) | 2025-03-18 | — | — | US | disclosed |
| US-20230092150-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | INOLEX INVESTMENT CORPORATION | 2023-03-23 | — | — | US | disclosed |
| US-11540991-B2 | Self-neutralizing amino acid based cationic compositions | INOLEX INVESTMENT CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12251457-B2 | Self-neutralizing amino acid based cationic compositions | SLC6A15, SLC1A5, SLC6A19 | TP53 2069/4885IARS1 2238/4885NOD1 4322/4885 |
| US-20250186322-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | SLC43A1, SLC1A5, SLC7A1 | TP53 1869/4885IARS1 1051/4885NOD1 2300/4885 |
| US-20230092150-A1 | Self-Neutralizing Amino Acid Based Cationic Compositions | SLC6A15, SLC1A5, SLC6A19 | TP53 2069/4885IARS1 2238/4885NOD1 4322/4885 |
| US-11540991-B2 | Self-neutralizing amino acid based cationic compositions | SLC6A15, SLC1A5, SLC6A19 | TP53 2069/4885IARS1 2238/4885NOD1 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.